On July 21, 2025, ZimVie (ZIMV) issued a press release announcing ZimVie’s entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED for $19.00 in cash per share. The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by ZimVie’s stockholders and receipt of applicable regulatory approvals. Upon completion of the transaction, ZimVie will become a privately held company and shares of ZimVie common stock will no longer be listed or publicly traded on the NASDAQ stock exchange. Due to the pending transaction, ZimVie will not host a conference call for the second quarter and ZimVie is withdrawing fiscal 2025 guidance. ZimVie’s previous financial guidance should not be relied upon.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZIMV:
- ZimVie will not host withdraws guidance amid ARCHIMED transaction
- ZimVie announces exclusive distribution agreement with Osstem Implant in China
- ZimVie upgraded to Equal Weight from Underweight at Barclays
- ZimVie Stock (ZIMV) Rockets 120% on ARCHIMED Deal
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!